A 58-year-old woman with established coronary artery disease (prior MI 2 years ago) is on atorvastatin 80 mg daily. Her current lipid panel shows: LDL-C 95 mg/dL, HDL-C 38 mg/dL, Triglycerides 280 mg/dL. She reports muscle pain in her legs that started 3 weeks after initiating atorvastatin and has not resolved despite dose reduction to 40 mg. Which of the following is the most appropriate next step in management?

Explanation

## Statin-Associated Muscle Symptoms (SAMS) **Key Point:** This patient has developed statin-associated myalgia (muscle pain without elevated CK) after initiating atorvastatin. Dose reduction alone has not resolved symptoms, indicating true statin intolerance rather than a dose-dependent effect. **High-Yield:** In patients with statin intolerance, the management algorithm is: 1. Confirm statin is the cause (temporal relationship, CK normal, symptoms resolve on withdrawal) 2. Try a different statin at lower dose (pravastatin, rosuvastatin at lower doses have lower myalgia risk) 3. If intolerance persists, switch to non-statin agents (ezetimibe, bempedoic acid, PCSK9 inhibitors) ## Statin Myalgia Risk Profile | Statin | Myalgia Risk | Mechanism | Notes | |--------|--------------|-----------|-------| | Atorvastatin | High | Lipophilic, high tissue penetration | Frequent culprit in SAMS | | Rosuvastatin | Moderate–High | Potent, hydrophilic | May cross-react; not ideal switch | | Pravastatin | Lower | Hydrophilic, minimal tissue penetration | Preferred alternative statin | | Simvastatin | High | Lipophilic | Avoid in statin-intolerant patients | **Clinical Pearl:** Pravastatin is the preferred statin to trial in patients with statin myalgia because of its hydrophilic nature and lower tissue accumulation. However, if myalgia persists with pravastatin, non-statin agents (bempedoic acid, ezetimibe, PCSK9 inhibitors) are the next step. **Mnemonic:** **SAMS Management** — Statin-Associated Muscle Symptoms: - **S**witch statin (try pravastatin or rosuvastatin at lower dose) - **A**ssess CK and symptoms (if CK >5× ULN, consider rhabdomyolysis) - **M**ove to non-statin if intolerance confirmed - **S**upport with CoQ10 (controversial but may help some patients) ## Why This Patient Needs a Non-Statin Option This patient has already tried atorvastatin at two doses (80 mg and 40 mg) with persistent myalgia. Switching to rosuvastatin (another potent statin) carries a high risk of cross-reactivity and recurrence of myalgia. Pravastatin is a reasonable trial, but given the severity and persistence of symptoms, a non-statin agent (bempedoic acid) is the most appropriate next step. **Warning:** Do NOT continue atorvastatin and add niacin — this does not address the statin intolerance and risks compounding myalgia and hepatotoxicity. Ezetimibe monotherapy alone is insufficient for a post-MI patient with LDL-C >70 mg/dL; it must be combined with a non-statin LDL-lowering agent. **Tip:** In post-MI patients with statin intolerance, bempedoic acid (a urate-lowering agent that also lowers LDL-C by ~18%) is increasingly used as a non-statin option to maintain cardiovascular protection.